Female patients of ESCC undergoing esophagectomy might benefit more from neoadjuvant chemotherapy

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000038344

Enrollment

Unknown

Registered

2020-09-20

Start date

2020-06-01

Completion date

Unknown

Last updated

2020-12-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal cancer

Interventions

Case series:Neoadjuvant chemotherapy and post-operative pathological diagnosis

Eligibility

Sex/Gender

All

Age

44 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patietns with diagnosis of esophageal cancer and have a clinical TNM stage 2. Esophageal cancer surgery was performed with surgical indications and without surgical contraindications 3. Aged over 18 and under 85 years.

Exclusion criteria

Exclusion criteria: 1. Patients unwilling to sign the informed consent; 2. Cachexia or severe organs failure such as cardiac dysfunction, and pulmonary insufficiency; 3. Pregnant or nursing females; 4. The researchers believe that exclusion is needed.

Design outcomes

Primary

Measure	Time frame
pathological complete response;	—

Secondary

Measure	Time frame
height;weight;BMI;	—

Countries

China

Contacts

Public ContactBinhui Ren

Jiangsu Cancer Hospital

renbinhui@jszlyy.com.cn+86 13813865205

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026